Iovance Biotherapeutics, Inc. (IOVA)

NASDAQ: IOVA · Real-Time Price · USD

10.25

+0.23 (2.30%)

At close: Sep 18, 2026, 4:00 PM EDT

10.22

-0.03 (-0.29%)

After-hours: Sep 18, 2026, 7:57 PM EDT

Iovance Biotherapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	324.97	263.5	164.07	1.19	-	-
Revenue Growth	34.55%	60.60%	13698.99%	-	-	-
Cost of Revenue	167.68	173.18	93.25	1.03	-	-
Gross Profit	157.29	90.32	70.82	0.16	-	-
Selling, General & Admin	149.18	152.32	152.27	106.1	104.1	83.66
Research & Development	267.71	300.27	276.23	333.19	294.78	259.04
Operating Expenses	453.45	488.53	466.1	460.72	398.88	342.7
Operating Income	-296.17	-398.21	-395.28	-460.56	-398.88	-342.7
Interest & Investment Income	1.95	3.11	4.51	9.44	3.46	6.46
EBT Excluding Unusual Items	-294.22	-395.11	-390.77	-451.12	-395.42	-336.24
Merger & Restructuring Charges	-5.14	-5.14	-	-	-	-
Gain (Loss) on Sale of Investments	5.59	7.2	10.26	3.61	-0.47	-6.01
Other Unusual Items	-	-	5.5	-	-	-
Pretax Income	-293.78	-393.05	-375.01	-447.52	-395.89	-342.25
Income Tax Expense	-4.26	-2.07	-2.83	-3.48	-	-
Net Income	-289.52	-390.98	-372.18	-444.04	-395.89	-342.25
Net Income to Common	-289.52	-390.98	-372.18	-444.04	-395.89	-342.25
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	410	357	290	235	159	153
Shares Outstanding (Diluted)	410	357	290	235	159	153
Shares Change	29.62%	23.28%	23.28%	47.64%	3.82%	10.92%
EPS (Basic)	-0.71	-1.09	-1.28	-1.89	-2.49	-2.23
EPS (Diluted)	-0.71	-1.09	-1.28	-1.89	-2.49	-2.23
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	-296.4	-336.24	-364.05	-384.11	-313.18	-265.52
Free Cash Flow Per Share	-0.72	-0.94	-1.26	-1.63	-1.97	-1.73
Gross Margin	48.40%	34.28%	43.17%	13.12%	-	-
Operating Margin	-91.14%	-151.12%	-240.92%	-38734.99%	-	-
Profit Margin	-89.09%	-148.38%	-226.84%	-37345.42%	-	-
Free Cash Flow Margin	-91.21%	-127.61%	-221.89%	-32305.30%	-	-
EBITDA	-259.6	-362.27	-357.64	-439.14	-389.57	-339.59
EBITDA Margin	-79.88%	-137.48%	-217.98%	-	-	-
D&A For EBITDA	36.56	35.94	37.63	21.42	9.31	3.11
EBIT	-296.17	-398.21	-395.28	-460.56	-398.88	-342.7
EBIT Margin	-91.14%	-151.12%	-240.92%	-	-	-
Revenue as Reported	324.97	263.5	164.07	1.19	-	-

SEC Filings: 10-K · 10-Q